State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province 730046, PR China.
Expert Rev Vaccines. 2013 Nov;12(11):1287-99. doi: 10.1586/14760584.2013.844652. Epub 2013 Oct 4.
Toxoplasmosis caused by the protozoan Toxoplasma gondii is a major public health problem, infecting one-third of the world human beings, and leads to abortion in domestic animals. A vaccine strategy would be an ideal tool for improving disease control. Many efforts have been made to develop vaccines against T. gondii to reduce oocyst shedding in cats and tissue cyst formation in mammals over the last 20 years, but only a live-attenuated vaccine based on the S48 strain has been licensed for veterinary use. Here, the authors review the recent development of T. gondii vaccines in cats, food-producing animals and mice, and present its future perspectives. However, a single or only a few antigen candidates revealed by various experimental studies are limited by only eliciting partial protective immunity against T. gondii. Future studies of T. gondii vaccines should include as many CTL epitopes as the live attenuated vaccines.
刚地弓形虫引起的弓形体病是一个主要的公共卫生问题，感染了世界上三分之一的人类，并导致家畜流产。疫苗接种策略将是改善疾病控制的理想工具。在过去的 20 年中，人们做出了许多努力来开发针对刚地弓形虫的疫苗，以减少猫体内卵囊的脱落和哺乳动物组织囊的形成，但只有基于 S48 株的减毒活疫苗被批准用于兽医使用。在这里，作者综述了近年来在猫、食用动物和小鼠中刚地弓形虫疫苗的研究进展，并提出了其未来的展望。然而，各种实验研究中发现的单一或少数抗原候选物仅能诱导对刚地弓形虫的部分保护性免疫，具有一定的局限性。未来的刚地弓形虫疫苗研究应该包括尽可能多的 CTL 表位，就像减毒活疫苗一样。
